Cyclacel Pharmaceuticals (CYCC) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares.
View CYCC analyst ratings or view top-rated stocks.

2 brokers have issued 1-year target prices for Cyclacel Pharmaceuticals' shares. Their CYCC share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 2,155.4% from the stock's current price.
View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts.

Cyclacel Pharmaceuticals' stock was trading at $0.6670 on January 1st, 2023. Since then, CYCC shares have decreased by 46.8% and is now trading at $0.3547.
View the best growth stocks for 2023 here.

Cyclacel Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 456,600 shares, an increase of 7.0% from the August 31st total of 426,900 shares. Based on an average daily trading volume, of 93,400 shares, the days-to-cover ratio is presently 4.9 days. Approximately 4.2% of the company's stock are short sold.
View Cyclacel Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CYCC earnings forecast.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Wednesday, August, 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.10. The biotechnology company earned $0.37 million during the quarter.

Shares of Cyclacel Pharmaceuticals reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYCC stock can currently be purchased for approximately $0.35.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) has a market capitalization of $4.48 million and generates $373,000.00 in revenue each year. The biotechnology company earns $-21,200,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

The company employs 2,018 workers across the globe.

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cyclacel.com. The biotechnology company can be reached via phone at (908) 517-7330, via email at ir@cyclacel.com, or via fax at 866-271-3466.